Terazosin, a drug developed originally to treat benign prostatic hyperplasia (BPH), may slow the progression of Parkinson’s Disease. It is thought that Terazosin may help by activating an enzyme (PGK1) which prevents cell death in the relevant brain regions. Further research is planned.
Roberts, M. (2019). Prostate drug may slow Parkinson’s disease. London: BBC Health News, September 17th 2019.
This relates to:
Cai, R. Zhang, Y. [and] Simmering, JE. [et al] (2019). Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases. Journal of Clinical Investigation. September 16th 2019. [Epub ahead of print].